SS-31 (Elamipretide): A Mitochondria-Targeting Peptide Under Study

What is SS-31?

SS-31 is a small synthetic peptide, also known by the name elamipretide. Unlike many peptides discussed in regenerative medicine, it has been developed and studied as a pharmaceutical candidate and has progressed into formal human clinical trials. Its distinguishing feature is where it goes inside the cell: SS-31 concentrates in the mitochondria, the structures responsible for producing most of a cell's energy.

Because mitochondrial dysfunction is thought to play a role in conditions ranging from inherited mitochondrial diseases to certain forms of heart failure, SS-31 has been investigated as a way to support mitochondrial function. It is important to be clear from the outset that SS-31 is investigational. It is not approved as a treatment in most jurisdictions, and the picture from human trials is nuanced rather than conclusive.

How it is thought to work

The proposed mechanism centers on a lipid called cardiolipin, which is found in the inner mitochondrial membrane. Cardiolipin helps organize the proteins of the electron transport chain, the machinery that mitochondria use to generate energy. When cardiolipin is disrupted, that machinery can become less efficient and produce more harmful reactive oxygen species.

SS-31 is described as binding to cardiolipin and helping stabilize the inner mitochondrial membrane. A 2025 review in the International Journal of Molecular Sciences laid out this cardiolipin-targeting mechanism and the surrounding trial landscape. The idea is that by supporting cardiolipin and membrane structure, the peptide may help preserve efficient energy production. This is the rationale behind the research; it is a mechanism, and a mechanism alone does not establish a clinical benefit in people.

What the research shows

The human evidence for SS-31 is more developed than for many peptides, which makes it worth examining carefully. The most rigorous test came in MMPOWER-3, a randomized controlled trial published in Neurology in 2023, which evaluated elamipretide in people with primary mitochondrial myopathy. This was a pivotal study of the cardiolipin-targeting approach in the disease it was most directly designed for, which is significant precisely because randomized controlled trials are the strongest form of clinical evidence.

On the cardiac side, the signal has been more encouraging in some respects. A 2017 randomized controlled trial in Circulation: Heart Failure reported that four weeks of intravenous elamipretide improved left ventricular volumes compared with placebo in patients with heart failure with reduced ejection fraction. The PROGRESS-HF Phase 2 trial, published in the Journal of Cardiac Failure in 2020, further examined the peptide's effects on left ventricular function in the same population.

Taken together, the research shows a peptide that has been studied seriously in humans with genuinely mixed results. There are measurable cardiac findings in earlier trials alongside a pivotal myopathy study whose primary outcome was not clearly met. That is why SS-31 remains investigational rather than an established therapy, and why honest framing matters more than optimism here.

What it is being explored for

Based on the evidence above, SS-31 is being explored primarily in two arenas: inherited mitochondrial myopathy, where energy production is impaired at the cellular level, and heart failure with reduced ejection fraction, where the heart muscle's energy demands are high and mitochondrial efficiency may matter.

Some interest in mitochondria-targeting peptides extends to broader questions of aging and tissue energy, since declining mitochondrial function is a recurring theme in longevity research. It is worth being cautious here. The supplied evidence concerns specific clinical conditions, not general anti-aging use, and extrapolating beyond what the trials tested would overstate what is actually known. SS-31 is a candidate under investigation, not a validated tool for healthy longevity.

How Strong Craft Regen approaches SS-31

Strong Craft Regen is a coordination and education service. We do not prescribe, and this article is educational only, not medical advice or a recommendation to use SS-31. For a compound like this, with advanced but mixed human data and an investigational regulatory status, that distinction matters.

Our role is to help you understand the evidence honestly and, where appropriate, to coordinate care delivered by the licensed physicians at Innovita Clinic in Vilnius, Lithuania. Any decision about whether an investigational peptide is suitable belongs with a qualified physician who can review your full health picture, weigh the limited and mixed evidence, and address regulatory considerations in your jurisdiction.

If you would like to learn more or discuss whether physician-supervised options make sense for your situation, you are welcome to book a call. We will give you a grounded, no-hype picture of what the research does and does not support.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. SS-31 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.